IONS Latest Press Releases

-- October 23, 2026 --

Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN) Business Wire 1:37 PM

-- October 22, 2026 --

Ionis ranked #1 on Science's Top Employers list Business Wire 2:25 PM

-- October 20, 2026 --

Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB) Business Wire 9:20 PM

-- October 16, 2026 --

TRYNGOLZA (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG) Business Wire 6:45 AM

-- September 23, 2026 --

Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN) Business Wire 1:00 AM

-- September 22, 2026 --

Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS Business Wire 8:00 AM

-- September 4, 2026 --

Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) Business Wire 4:41 PM

-- September 3, 2026 --

ZANVASTRO (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients Business Wire 7:47 PM

Ionis to present at upcoming investor conferences Business Wire 7:05 AM

-- August 20, 2026 --

Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 Business Wire 7:00 AM

-- August 8, 2026 --

IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law Business Wire 4:07 PM

-- August 6, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS PRNewswire 11:02 PM

-- August 4, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS Globe Newswire 5:15 PM

-- July 30, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS PRNewswire 10:01 AM

-- July 29, 2026 --

Ionis announces Dr. Frank Bennett, chief scientific officer, to retire Business Wire 7:05 AM

Ionis reports second quarter 2026 financial results and highlights progress on key programs Business Wire 7:00 AM

-- July 28, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS Globe Newswire 5:03 PM

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS Globe Newswire 12:46 PM

-- July 23, 2026 --

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS PRNewswire 11:30 AM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS PRNewswire 10:01 AM

-- July 16, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS PRNewswire 10:00 AM

-- July 15, 2026 --

Ionis to hold second quarter 2026 financial results webcast Business Wire 7:05 AM

-- July 14, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS Globe Newswire 5:00 PM

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS Globe Newswire 12:17 PM

Levi & Korsinsky Notifies Investors of a Pending Investigation Into Securities Claims Involving Ionis Pharmaceuticals (IONS) Globe Newswire 10:20 AM

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease Business Wire 9:16 AM

-- July 13, 2026 --

IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS) Business Wire 10:00 AM

Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome Business Wire 7:00 AM

-- July 10, 2026 --

IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals PRNewswire 9:00 AM

-- July 9, 2026 --

Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of a Pending Investigation Into Ionis Pharmaceuticals (IONS) PRNewswire 8:57 PM

Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy Business Wire 2:00 AM

-- July 6, 2026 --

Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome Business Wire 7:00 AM

-- June 25, 2026 --

Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S. Business Wire 2:59 AM

-- June 24, 2026 --

TRYNGOLZA (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG) Business Wire 2:37 PM

-- June 8, 2026 --

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors Business Wire 7:00 AM

-- June 4, 2026 --

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses Business Wire 7:00 AM

-- May 28, 2026 --

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B Business Wire 4:45 AM